B01AA07 - Acenocoumarol |
Propably not porphyrinogenic |
PNP |
Rationale
Acenocoumarol is metabolized by CYP 2C9, 1A2 and 2C19, but induction or inhibition of the CYP enzymes are not observed or suspected.
Chemical description
Acenocoumarol is a coumarin derivate.
Therapeutic characteristics
Acenocoumarol is a coumarin derivative and functions as vitamin K antagonist. It is used in the treatment and prevention of thromboembolic diseases.
It is administered orally and the elimination half-life from the plasma is from 8 to 11 hours.
Metabolism and pharmacokinetics
Acenocoumarol is metabolized mainly by CYP 2C9, but CYP1A2 and CYP 2C19 are also involved (Thijssen 2000, Ufer 2005).
No CYP relevant drug-drug interaction with acenocoumarol as a perpetrator has been reported in the literature (Lexi-Interact, Micromedex, SPC).
IPNet drug reports
Uneventful use reported in 5 patients with acute porphyria.
References
- Scientific articles
- Thijssen HH, Flinois JP et al. Cytochrome P4502C9 is the principal catalyst of racemic acenocoumarol hydroxylation reactions in human liver microsomes. Drug Metab Dispos. 2000 Nov;28(11):1284-90. PMID 11038154. #4366
- Ufer M. Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol. Clin Pharmacokinet. 2005;44(12):1227-46. PMID 16372822. #1155
- Drug interaction databases
- Lexi-Interact, via UpToDate. #1152
- Micromedex® 2.0 (online). Drug Interactions). (24.05.2017). #1153
- Summary of Product Characteristics
- The electronic Medicines Compendium (emc). Summary of Product Characteristics (SPC).Sinthrome. #1157
Similar drugs
© NAPOS 2024